Neurogenic Detrusor Overactivity Forecast Report 2025 – Designed for Product & Growth Teams

 Unlock 30% off global market reports with code ONLINE30 — get insights on tariff changes, macro trends, and global economic shifts.

 

 What is the current market size of the neurogenic detrusor overactivity industry, and what growth rate is it expected to achieve?
 The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, rising awareness among healthcare professionals, growing adoption of pharmaceutical interventions, expansion of hospital and clinic infrastructure, and increasing diagnosis rates.
 
 The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to a rising aging population, a growing prevalence of spinal cord injuries, increasing healthcare expenditure, expansion of minimally invasive treatment options, and rising patient awareness and education. Major trends in the forecast period include technology advancements in stem cell approaches, innovations in drug delivery systems, developments in neuromodulation devices, research and development in personalized medicine, and advancements in minimally invasive procedures.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
 
 What are the major drivers contributing to the growth of the neurogenic detrusor overactivity market?
 The rising incidence of neurological disorders is expected to propel the growth of the neurogenic detrusor overactivity market going forward. Neurological disorders refer to medical conditions that affect the brain, spinal cord, or nerves, leading to problems with movement, sensation, cognition, or other bodily functions. Neurological disorders are rising as people are living longer, which increases the chances of age-related brain degeneration. Neurogenic detrusor overactivity (NDO) is a bladder dysfunction commonly associated with neurological disorders, such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions disrupt normal nerve signaling between the brain and bladder, leading to involuntary bladder contractions. For instance, in April 2024, according to a study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, there will be an estimated 4.9 billion cases of brain disorders globally by 2050, a 22% increase from approximately 4 billion cases in 2021. Therefore, the rising incidence of neurological disorders is driving growth in the neurogenic detrusor overactivity market.
 
 What are the major market segments driving the growth of the neurogenic detrusor overactivity industry?
 The neurogenic detrusor overactivity market covered in this report is segmented –
 
 1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
 2) By Application: Adult, Child
 3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
 
 Subsegments:
 1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
 2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
 3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report
 
 What evolving trends are creating new opportunities in the neurogenic detrusor overactivity market?
 Major companies operating in the neurogenic detrusor overactivity (NDO) treatment market are focusing on developing advanced generic therapeutics such as beta-3 adrenergic receptor agonists to deliver effective bladder control solutions at reduced costs. Beta-3 adrenergic receptor agonists, such as mirabegron, function by relaxing the detrusor muscle in the bladder, thereby increasing bladder capacity and reducing symptoms such as urgency and incontinence. For instance, in April 2024, Lupin Ltd., an India-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, the generic version of Myrbetriq, in the United States. As an advanced once-daily oral therapy, Mirabegron offers a convenient and effective treatment option for patients with overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) in pediatric populations. This approval reinforces Lupin’s commitment to expanding access to high-quality, affordable generic medications in critical therapeutic areas.
 
 Who are the key market players contributing to the growth of the neurogenic detrusor overactivity industry?
 Major companies operating in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., Hugel Inc.
 
 Which regions are leading the growth of the neurogenic detrusor overactivity market globally?
 North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Neurogenic Detrusor Overactivity Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24619
 
 Need Customized Data On Neurogenic Detrusor Overactivity Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=24619&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Americas +1 310–496-7795
 Asia +44 2071930708
 Europe +44 7882 955267
 Email us at info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company